Home > Riviste > Minerva Obstetrics and Gynecology > Fascicoli precedenti > Articles online first > Minerva Obstetrics and Gynecology 2021 Dec 14

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Obstetrics and Gynecology 2021 Dec 14

DOI: 10.23736/S2724-606X.21.04954-X

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Dydrogesterone supplementation in addition to routine micronized progesterone administration for luteal support in cycles triggered with lone GnRH agonist results in an acceptable pregnancy rate and avoids the need to freeze embryos

Myriam SAFRAI , Shmuel HERTSBERG, Assaf BEN-MEIR, Benjamin REUBINOFF, Tal IMBAR, Talya MORDECHAI-DANIEL, Simon ALEXANDER

IVF Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel


PDF


BACKGROUND: Ovarian hyperstimulation syndrome (OHSS) is reduced when using antagonist cycle with gonadotrophin releasing hormone (GnRH) agonist trigger before ovum pick up. This trigger induces short luteinizing hormone (LH) and follicle stimulating hormone (FSH) peaks, resulting in an inadequate luteal phase and a reduced implantation rate. We assessed whether the luteal phase can be rescued by supplementing with oral Dydrogesterone (Duphaston) in antagonist cycles after a lone GnRH agonist trigger.
METHODS: A retrospective cohort study. The study group (n=123) included women who underwent IVF. Patients received a GnRH-antagonist with a lone GnRH-agonist trigger due to imminent OHSS. The control group (n=374) included patients who underwent a standard antagonist protocol with a dual trigger of a GnRH-agonist and human chorionic gonadotrophin (hCG). All the patients were treated with micronized progesterone (Utrogestan) for luteal phase support. Study patients were given Duphaston in addition.
RESULTS: The fertilization rate was comparable between the two groups. The mean number of embryos transferred, the clinical pregnancy rate and the take-home baby rate were comparable between groups (1.5 ± 0.6 vs. 1.5 ± 0.5 and 46.3% vs. 41.2%, and 66.7% vs. 87.7%, respectively). No OHSS event was reported in either group.
CONCLUSIONS: This study was the first to evaluate outcomes of Duphaston supplementation for luteal support in an antagonist cycle with lone GnRH agonist trigger. The functionality of the luteal phase of those cycles could be restored by adding Duphaston. This approach was found to be safe and prevented the need to postpone embryo transfer in case of pending OHSS.


KEY WORDS: Antagonist; Ovarian hyperstimulation syndrome, OHSS; Dydrogesterone; Duphaston

inizio pagina